title: Regulatory T cells control macrophage accumulation and activation in lymphoma.
abstract: Strategies of manipulating immunosuppressive regulatory T cells (Treg) in cancer patients are currently evaluated in clinical trials. Treg suppress immune responses of tumor-specific T cells; yet, relatively little is known about the impact of Treg on innate immune cells in tumor models in vivo. Many tumors lose expression of MHC class I. Therefore, our study aimed at defining strategies to strengthen immune responses against a high tumor burden of the MHC class I-deficient mouse lymphoma RMA-S. We demonstrate that Treg depletion in mice led to tumor rejection that was dependent on T cells, NK cells and IFN-gamma. In the absence of Treg elevated levels of IFN-gamma were produced by tumor-infiltrating T cells and NK cells. Tumor rejection observed in the absence of Treg correlated with a substantial IFN-gamma-dependent increase in the numbers of tumor-infiltrating leukocytes. The most abundant cell population in the tumors was macrophages. Tumor-infiltrating macrophages from Treg-depleted mice expressed increased amounts of MHC class II, produced highly enhanced levels of pro-inflammatory cytokines and inhibited tumor cell proliferation. It was reported that tumor-infiltrating macrophages have multi-faceted functions promoting or counteracting tumor growth. In our study, high numbers of macrophages infiltrating RMA-S tumors in the absence of Treg correlated with tumor rejection suggesting that macrophages are additional targets for Treg-mediated immune suppression in cancer.
authors.affiliation: Boveri junior research group of Innate Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany.
authors.forename: Ioanna E
authors.initials: IE
authors.lastname: Galani
authors.forename: Marco
authors.initials: M
authors.lastname: Wendel
authors.forename: Ana
authors.initials: A
authors.lastname: Stojanovic
authors.forename: Maria
authors.initials: M
authors.lastname: Jesiak
authors.forename: Margareta M
authors.initials: MM
authors.lastname: Müller
authors.forename: Carola
authors.initials: C
authors.lastname: Schellack
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Suri-Payer
authors.forename: Adelheid
authors.initials: A
authors.lastname: Cerwenka
mesh_terms: D000818:Animals; D016207:Cytokines / Q000378:metabolism; D003602:Cytotoxicity, Immunologic; D005434:Flow Cytometry; D005805:Genes, MHC Class I / Q000502:physiology; D005802:Genes, MHC Class II / Q000502:physiology; D007124:Immunoenzyme Techniques; D007371:Interferon-gamma / Q000378:metabolism; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation; D008223:Lymphoma / Q000276:immunology* / Q000473:pathology; D008262:Macrophage Activation / Q000276:immunology*; D008264:Macrophages / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D017471:Receptors, Interferon / Q000502:physiology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000502:physiology*; D000096743:Interferon gamma Receptor
chemical_list: D016207:Cytokines; D007371:Interferon-gamma; D017471:Receptors, Interferon; D000096743:Interferon gamma Receptor